한글목차

세계의 올리고뉴클레오티드 접합체 시장 규모는 2024년에 1억 6,920만 달러로 추정되며, 2025년부터 2031년까지 예측 기간 동안 CAGR 40.36%로 확대되어 2031년까지 17억 6,880만 달러에 달할 것으로 예측됩니다.

북미의 올리고뉴클레오티드 접합체 시장은 2024년에 7,298만 달러로 평가되며 2025년부터 2031년까지 예측 기간 동안 39.28%의 CAGR로 2031년까지 7억 1,990만 달러에 달할 것으로 예상됩니다.

아시아태평양의 올리고뉴클레오티드 접합체 시장은 2024년에 4,389만 달러로 평가되며 2025년부터 2031년까지 예측 기간 동안 43.72%의 CAGR로 2031년까지 5억 4,267만 달러에 달할 것으로 예상됩니다.

유럽의 올리고뉴클레오티드 접합체 시장은 2024년 4,529만 달러로 평가되며 2025년부터 2031년까지 예측 기간 동안 38.89%의 CAGR로 성장하여 2031년에는 4억 4,326만 달러에 달할 것으로 예상됩니다.

2024년 기준 올리고뉴클레오티드 접합체의 세계 주요 기업으로는 WuXi TIDES, Bachem, Lonza, BioSpring, GenScript, Medtide(CPC Scientific), Pharmaron, Bio-Synthesis, Kaneka Corporation(Eurogentec) 등이 있습니다. Inc, Kaneka Corporation(Eurogentec) 등이 있습니다. 세계 상위 5개 기업은 매출액 기준으로 약 72%의 점유율을 차지하고 있습니다.

이 보고서는 올리고뉴클레오티드 접합체 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가, 유형 및 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.

올리고뉴클레오티드 접합체 시장의 규모, 추정 및 예측은 2024년을 기준 연도로 하여 2020년에서 2031년까지의 과거 데이터와 예측 데이터를 포함하는 매출 수익으로 제시되었습니다. 정량적, 정성적 분석을 통해 독자들이 비즈니스/성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 포지셔닝 분석, 올리고뉴클레오티드 접합체 관련 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 도와드립니다.

시장 세분화

기업별

• WuXi TIDES
• Bachem
• Lonza
• BioSpring
• GenScript
• Medtide(CPC Scientific)
• Kaneka Corporation(Eurogentec)
• Olon(GTP Bioways)
• Abzena
• 3PBIOVIAN
• Bio-Synthesis Inc
• ChemExpress
• Creative Biolabs
• HitGen
• Pharmaron
• Suzhou Biosyntech
• Creative Biogene(IntegrateRNA)

유형별 부문

• 올리고뉴클레오티드-펩타이드
• 올리고뉴클레오티드-항체
• 올리고뉴클레오티드-GalNAc
• 올리고뉴클레오티드-지질
• 기타

용도별 부문

• 유전자 치료
• 약물전달
• 백신 개발

지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 한국
  • 동남아시아
  • 인도
  • 호주
  • 기타 아시아태평양
• 유럽
  • 독일
  • 영국
  • 스위스
  • 벨기에
  • 프랑스
  • 기타 유럽
• 라틴아메리카
  • 멕시코
  • 브라질
  • 기타 라틴아메리카
• 중동 및 아프리카

영문목차

The global market for Oligonucleotide Conjugates was estimated to be worth US$ 169.2 million in 2024 and is forecast to a readjusted size of US$ 1,768.8 million by 2031 with a CAGR of 40.36% during the forecast period 2025-2031.

North American market for Oligonucleotide Conjugates was valued at $ 72.98 million in 2024 and will reach $ 719.9 million by 2031, at a CAGR of 39.28% during the forecast period of 2025 through 2031.

Asia-Pacific market for Oligonucleotide Conjugates was valued at $ 43.89 million in 2024 and will reach $ 542.67 million by 2031, at a CAGR of 43.72% during the forecast period of 2025 through 2031.

Europe market for Oligonucleotide Conjugates was valued at $ 45.29 million in 2024 and will reach $ 443.26 million by 2031, at a CAGR of 38.89% during the forecast period of 2025 through 2031.

The global key companies of Oligonucleotide Conjugates include WuXi TIDES, Bachem, Lonza, BioSpring, GenScript, Medtide (CPC Scientific), Pharmaron, Bio-Synthesis Inc, and Kaneka Corporation (Eurogentec), etc. in 2024, the global five largest players hold a share approximately 72% in terms of revenue.

This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Conjugates, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Oligonucleotide Conjugates by region & country, by Type, and by Application.

The Oligonucleotide Conjugates market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Conjugates.

Market Segmentation

By Company

• WuXi TIDES
• Bachem
• Lonza
• BioSpring
• GenScript
• Medtide(CPC Scientific)
• Kaneka Corporation(Eurogentec)
• Olon(GTP Bioways)
• Abzena
• 3PBIOVIAN
• Bio-Synthesis Inc
• ChemExpress
• Creative Biolabs
• HitGen
• Pharmaron
• Suzhou Biosyntech
• Creative Biogene (IntegrateRNA)

Segment by Type

• Oligonucleotide-Peptide
• Oligonucleotide-Antibody
• Oligonucleotide-GalNAc
• Oligonucleotide-Lipid
• Other

Segment by Application

• Gene Therapy
• Drug Delivery
• Vaccine Development

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • U.K.
  • Switzerland
  • Belgium
  • France
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Oligonucleotide Conjugates company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Oligonucleotide Conjugates in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Oligonucleotide Conjugates in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Oligonucleotide Conjugates Product Introduction
• 1.2 Global Oligonucleotide Conjugates Market Size Forecast (2020-2031)
• 1.3 Oligonucleotide Conjugates Market Trends & Drivers
  • 1.3.1 Oligonucleotide Conjugates Industry Trends
  • 1.3.2 Oligonucleotide Conjugates Market Drivers & Opportunity
  • 1.3.3 Oligonucleotide Conjugates Market Challenges
  • 1.3.4 Oligonucleotide Conjugates Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Oligonucleotide Conjugates Players Revenue Ranking (2024)
• 2.2 Global Oligonucleotide Conjugates Revenue by Company (2020-2025)
• 2.3 Key Companies Oligonucleotide Conjugates Product Offered
• 2.4 Key Companies Time to Establish
• 2.5 Oligonucleotide Conjugates Market Competitive Analysis
  • 2.5.1 Oligonucleotide Conjugates Market Concentration Rate (2020-2025)
  • 2.5.2 Global 5 and 10 Largest Companies by Oligonucleotide Conjugates Revenue in 2024
  • 2.5.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Conjugates as of 2024)
• 2.6 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Oligonucleotide-Peptide
  • 3.1.2 Oligonucleotide-Antibody
  • 3.1.3 Oligonucleotide-GalNAc
  • 3.1.4 Oligonucleotide-Lipid
  • 3.1.5 Other
• 3.2 Global Oligonucleotide Conjugates Sales Value by Type
  • 3.2.1 Global Oligonucleotide Conjugates Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Oligonucleotide Conjugates Sales Value, by Type (2020-2031)
  • 3.2.3 Global Oligonucleotide Conjugates Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Gene Therapy
  • 4.1.2 Drug Delivery
  • 4.1.3 Vaccine Development
• 4.2 Global Oligonucleotide Conjugates Sales Value by Application
  • 4.2.1 Global Oligonucleotide Conjugates Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Oligonucleotide Conjugates Sales Value, by Application (2020-2031)
  • 4.2.3 Global Oligonucleotide Conjugates Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Oligonucleotide Conjugates Sales Value by Region
  • 5.1.1 Global Oligonucleotide Conjugates Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Oligonucleotide Conjugates Sales Value by Region (2020-2025)
  • 5.1.3 Global Oligonucleotide Conjugates Sales Value by Region (2026-2031)
  • 5.1.4 Global Oligonucleotide Conjugates Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Oligonucleotide Conjugates Sales Value, 2020-2031
  • 5.2.2 North America Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Oligonucleotide Conjugates Sales Value, 2020-2031
  • 5.3.2 Europe Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Oligonucleotide Conjugates Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Oligonucleotide Conjugates Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Oligonucleotide Conjugates Sales Value, 2020-2031
  • 5.5.2 South America Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Oligonucleotide Conjugates Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Oligonucleotide Conjugates Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Oligonucleotide Conjugates Sales Value, 2020-2031
  • 6.3.2 United States Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Oligonucleotide Conjugates Sales Value, 2020-2031
  • 6.4.2 Europe Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Oligonucleotide Conjugates Sales Value, 2020-2031
  • 6.5.2 China Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Oligonucleotide Conjugates Sales Value, 2020-2031
  • 6.6.2 Japan Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Oligonucleotide Conjugates Sales Value, 2020-2031
  • 6.7.2 South Korea Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031
• 6.8 Australia
  • 6.8.1 Australia Oligonucleotide Conjugates Sales Value, 2020-2031
  • 6.8.2 Australia Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Australia Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Oligonucleotide Conjugates Sales Value, 2020-2031
  • 6.9.2 India Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 WuXi TIDES
  • 7.1.1 WuXi TIDES Profile
  • 7.1.2 WuXi TIDES Main Business
  • 7.1.3 WuXi TIDES Oligonucleotide Conjugates Products, Services and Solutions
  • 7.1.4 WuXi TIDES Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
  • 7.1.5 WuXi TIDES Recent Developments
• 7.2 Bachem
  • 7.2.1 Bachem Profile
  • 7.2.2 Bachem Main Business
  • 7.2.3 Bachem Oligonucleotide Conjugates Products, Services and Solutions
  • 7.2.4 Bachem Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Bachem Recent Developments
• 7.3 Lonza
  • 7.3.1 Lonza Profile
  • 7.3.2 Lonza Main Business
  • 7.3.3 Lonza Oligonucleotide Conjugates Products, Services and Solutions
  • 7.3.4 Lonza Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Lonza Recent Developments
• 7.4 BioSpring
  • 7.4.1 BioSpring Profile
  • 7.4.2 BioSpring Main Business
  • 7.4.3 BioSpring Oligonucleotide Conjugates Products, Services and Solutions
  • 7.4.4 BioSpring Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
  • 7.4.5 BioSpring Recent Developments
• 7.5 GenScript
  • 7.5.1 GenScript Profile
  • 7.5.2 GenScript Main Business
  • 7.5.3 GenScript Oligonucleotide Conjugates Products, Services and Solutions
  • 7.5.4 GenScript Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
• 7.6 Medtide (CPC Scientific)
  • 7.6.1 Medtide (CPC Scientific) Profile
  • 7.6.2 Medtide (CPC Scientific) Main Business
  • 7.6.3 Medtide (CPC Scientific) Oligonucleotide Conjugates Products, Services and Solutions
  • 7.6.4 Medtide (CPC Scientific) Oligonucleotide Conjugates Revenue (US$ Million) & (2022-2025)
  • 7.6.5 Medtide (CPC Scientific) Recent Developments
• 7.7 Kaneka Corporation (Eurogentec)
  • 7.7.1 Kaneka Corporation (Eurogentec) Profile
  • 7.7.2 Kaneka Corporation (Eurogentec) Main Business
  • 7.7.3 Kaneka Corporation (Eurogentec) Oligonucleotide Conjugates Products, Services and Solutions
  • 7.7.4 Kaneka Corporation (Eurogentec) Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
• 7.8 Olon (GTP Bioways)
  • 7.8.1 Olon (GTP Bioways) Profile
  • 7.8.2 Olon (GTP Bioways) Main Business
  • 7.8.3 Olon (GTP Bioways) Oligonucleotide Conjugates Products, Services and Solutions
  • 7.8.4 Olon (GTP Bioways) Oligonucleotide Conjugates Revenue (US$ Million) & (2023-2025)
  • 7.8.5 Olon (GTP Bioways) Recent Developments
• 7.9 Abzena
  • 7.9.1 Abzena Profile
  • 7.9.2 Abzena Main Business
  • 7.9.3 Abzena Oligonucleotide Conjugates Products, Services and Solutions
  • 7.9.4 Abzena Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
• 7.10 3PBIOVIAN
  • 7.10.1 3PBIOVIAN Profile
  • 7.10.2 3PBIOVIAN Main Business
  • 7.10.3 3PBIOVIAN Oligonucleotide Conjugates Products, Services and Solutions
  • 7.10.4 3PBIOVIAN Oligonucleotide Conjugates Revenue (US$ Million) & (2022-2025)
• 7.11 Bio-Synthesis Inc
  • 7.11.1 Bio-Synthesis Inc Profile
  • 7.11.2 Bio-Synthesis Inc Main Business
  • 7.11.3 Bio-Synthesis Inc Oligonucleotide Conjugates Products, Services and Solutions
  • 7.11.4 Bio-Synthesis Inc Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
• 7.12 ChemExpress
  • 7.12.1 ChemExpress Profile
  • 7.12.2 ChemExpress Main Business
  • 7.12.3 ChemExpress Oligonucleotide Conjugates Products, Services and Solutions
  • 7.12.4 ChemExpress Oligonucleotide Conjugates Revenue (US$ Million) & (2023-2025)
• 7.13 Creative Biolabs
  • 7.13.1 Creative Biolabs Profile
  • 7.13.2 Creative Biolabs Main Business
  • 7.13.3 Creative Biolabs Oligonucleotide Conjugates Products, Services and Solutions
  • 7.13.4 Creative Biolabs Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
• 7.14 HitGen
  • 7.14.1 HitGen Profile
  • 7.14.2 HitGen Main Business
  • 7.14.3 HitGen Oligonucleotide Conjugates Products, Services and Solutions
  • 7.14.4 HitGen Oligonucleotide Conjugates Revenue (US$ Million) & (2023-2025)
• 7.15 Pharmaron
  • 7.15.1 Pharmaron Profile
  • 7.15.2 Pharmaron Main Business
  • 7.15.3 Pharmaron Oligonucleotide Conjugates Products, Services and Solutions
  • 7.15.4 Pharmaron Oligonucleotide Conjugates Revenue (US$ Million) & (2024-2025)
• 7.16 Suzhou Biosyntech
  • 7.16.1 Suzhou Biosyntech Profile
  • 7.16.2 Suzhou Biosyntech Main Business
  • 7.16.3 Suzhou Biosyntech Oligonucleotide Conjugates Products, Services and Solutions
  • 7.16.4 Suzhou Biosyntech Oligonucleotide Conjugates Revenue (US$ Million) & (2024-2025)
• 7.17 Creative Biogene (IntegrateRNA)
  • 7.17.1 Creative Biogene (IntegrateRNA) Profile
  • 7.17.2 Creative Biogene (IntegrateRNA) Main Business
  • 7.17.3 Creative Biogene (IntegrateRNA) Oligonucleotide Conjugates Products, Services and Solutions
  • 7.17.4 Creative Biogene (IntegrateRNA) Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)

8 Industry Chain Analysis

• 8.1 Oligonucleotide Conjugates Industrial Chain
• 8.2 Oligonucleotide Conjugates Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
  • 10.1.2 Data Source
• 10.2 Author Details
• 10.3 Disclaimer